Trial Profile

Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esomeprazole (Primary)
Indications Anaemia; Beta-thalassaemia; Congenital-dyserythropoietic-anemia; Haemochromatosis; Iron overload; Sickle cell anaemia; Sideroblastic anaemia
Focus Therapeutic Use
Acronyms PPI Shine Again

21 Oct 2021 Status changed from active, no longer recruiting to completed.
23 Jun 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
06 Nov 2019 According to trial design released at 61st Annual Meeting and Exposition of the American Society of Hematology, Results are expected Q3 2020. The trial is funded by ZonMW, The Netherlands Organization for Health and Research Development, and by the Innovatiefonds Zorgverzekeraars.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com